Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Change in number of shares and votes in ÅF AB (publ)

The eighth opportunity to convert debentures into shares under the staff convertible debenture program decided by the Annual General Meeting 2015 occurred in February 2019. Through the conversion the numbers of B-shares and votes have increased by 39 146. Before the conversion: A-shares: 3 217 752B-shares: 74 158 951Total shares: 77 376 703Votes: 106 336 471 After the conversion: A-shares: 3 217 752B-shares: 74 198 097Total shares: 77 415 849Votes: 106 375 617 Corporate CommunicationÅF AB (publ) The information contained

Conversion of shares

According to Husqvarna AB´s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in Husqvarna AB. When such a conversion has occurred, the company is obligated by the Act on Trading in Financial Instruments to disclose any such change. In February 2019, at the request of shareholders, 51,003 Class A shares were converted to Class B shares. The total number of votes thereafter amounts to 158,697,241.7. The total number of registered shares in the company amounts to 576,343,778

Sandvik Capital Markets Day 2019

On May 21-22, 2019, Sandvik will arrange its Capital Markets Day in Tampere, Finland, at the production facility and test mine of Sandvik Mining and Rock Technology. The Capital Markets Day provides an opportunity for institutional investors, financial analysts and financial media to get an update on the strategy and development of Sandvik. The Capital Markets Day will commence with a casual dinner on May 21. On May 22, presentations will be held by Björn Rosengren, President and CEO and Tomas Eliasson, CFO as well as by business area management. Participants will also get a guided

Envirotainer Opens RAP e2 Station in Shanghai

February 28th, 2018 - Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, today announced that they are expanding their RAP e2 network in Asia-Pacific by adding Shanghai (PVG), China to the growing list of RAP e2 stations across the world. Shanghai is the 31st station in the Envirotainer network carrying the flagship RAP e2 solution when it opens on March 1st, 2019. This is part of Envirotainer’s strategy to meet the increasing demand for secure airfreight shipments of pharmaceuticals requiring temperature control.“Asia-Pacific, and

U.S. Cellular selects Ericsson for 5G deployments

· Multi-year contract for Ericsson to provide U.S. Cellular with 3GPP standards-based 5G NR hardware and software · Ericsson’s product and support services allow U.S. Cellular to rapidly deploy 5G · Selection follows successful joint testing of various 5G use casesU.S. Cellular (NYSE: USM) and Ericsson (NASDAQ: ERIC) today announced a multi-year contract for Ericsson to support U.S. Cellular’s 5G network deployment. Under the contract, Ericsson will provide U.S. Cellular with 3GPP standards-based 5G New Radio (NR) hardware and software. Ericsson will support U.S. Cellular’s network

New number of shares and votes in Dustin Group AB (publ)

The long-term incentive program for senior executives introduced at the annual general meeting on 19 January 2019, entitles the holder of warrants to subscribe for new shares in the company during the first half of 2019. In February, a total of 151,241 shares have been issued through the exercise of warrants received from the incentive program. Prior to the issue of the new shares, there were 88,258,859 shares and votes in the company. As of 28 February 2019, there are a total of 88,410,100 shares and votes in the company. For further information, please contact: Eva Ernfors, Head of

BONESUPPORT HOLDING AB (publ) – Full Year Report 2018

In a press release published on February 27 at 08.00 regarding BONESUPPORT HOLDING AB, the full-year report was included as a link. With this press release the report is included as an attachment. The report is also available on BONESUPPORT's website. Lund, Sweden, 09.00 CET, 28 February 2018 – BONESUPPORT HOLDING AB (publ) - listed on Nasdaq Stockholm - an emerging leader in orthobiologics for the management of bone voids, today publish the financial report for the fourth quarter and the full year 2018. POSITIVE RESULTS FROM THE CERTIFY STUDY AND CONTINUED STRONG GROWTH IN EUROPE1

Annual Report 2018 for Hufvudstaden

Hufvudstaden Annual Report for 2018 is now available on our website www.hufvudstaden.se. A printed version will be distributed to all new shareholders and to other shareholders by request. Stockholm February 28, 2019HUFVUDSTADEN AB (publ) Questions can be answered by Åsa Roslund, CFO, telephone +46 8 762 90 00.  The information is information that Hufvudstaden AB (publ) is obliged to publish according to the Swedish Securities Market Act. The information was submitted for publication on February 28, 2019 at 09:00am CET.

ZINZINO AB (PUBL): YEAR-END REPORT 2018

STRONG IMPROVEMENT IN PROFIT POSSIBLE INCREASE SHARE DIVIDENDImproved profit, strong balance sheet and good liquid assets results in the proposal of the board to pay out an ordinary dividend of SEK 0.50 (SEK 45) and an extra dividend ofSEK 0.20 (-) to the shareholders for the past year. The increased share of Zinzino Health in the product mix during the year combined with improved cost control resulted in a sharp increase in gross profit. In combination with scaling from other activities, it resulted that the EBITDA increased to SEK 2.2 M (-2.3) for the fourth quarter and doubled

UPM Annual Report 2018 published

UPM-Kymmene Corporation         Annual Financial Report         28 February 2019 at 10:00 EET UPM Annual Report 2018 published UPM's Annual Report 2018 has been published online at www.upm.com and www.upm.fi. The Annual Report including the company's Financial Statements and the Report of the Board of Directors for the period 1 January - 31 December 2018 is available in English and Finnish as a PDF file on the corporate website. UPM has also published its Corporate Governance Statement 2018 and the Remuneration Statement dated 28 February 2019 on the corporate website in the

STRAX:  YEAR-END REPORT FOR THE FINANCIAL YEAR 2018

STRAX delivers a record year with sales of MEUR 107 and net income of MEUR 17The Group’s sales for the period January 1 – December 31, 2018, amounted toMEUR 107.0 (100.1), corresponding to a growth of 6.9 percent, with a gross margin of 24 (28) percent. The Group’s result for the period January 1 – December 31, 2018, amounted to MEUR16.7 (1.8) corresponding to EUR 0.14 (0.02) per share. Equity as of December 31, 2018 amounted to MEUR 34.3 (21.0) corresponding to EUR 0.28 (0.18) per share. EBITDA for the period January 1 – December 31, 2018, amounted to MEUR 6.7 (9.3). On

Hexagon Composites ASA - Fixed income investor meetings and contemplated bond issue

Hexagon Composites ASA has mandated DNB Markets as Sole Bookrunner to arrange a series of fixed income investor meetings in the Nordics, commencing on Monday, 4 March.  A NOK 1,100 million senior unsecured 4 year floating rate issue is expected to follow, subject to market conditions. For more information:David Bandele, CFO, Hexagon Composites ASATelephone: +47 920 91 483 | david.bandele@hexagongroup.com  Hiva Ghiri, VP Investor Relations, Hexagon Composites ASATelephone: +47 958 66 790 | hiva.ghiri@hexagongroup.com About Hexagon Composites ASAHexagon delivers safe and

Change in number of shares in BrainCool AB (publ)

Conversion of convertible notes into shares, as part of the financing agreements announced 24 August and 5 November, 2018.The number of convertible notes converted on February 27, was 9. The number of convertible notes remaining under the second tranche for future conversion is 0. The number of convertible notes remaining under the third tranche is 43. The number of shares and the number of votes before the conversion was 38 388 342. Through this conversion, and once the shares from the conversion will be registered at Bolagsverket, the number of shares and the number of votes shall have

Flowscape receives large room panel order from international corporate customer

In conjunction with an ongoing global rollout of the Flowscape system for an international corporate customer, Flowscape has received a large order for room panels worth SEK 2 million.The order is part of a major framework agreement between the international corporate customer and Flowscape, where the Flowscape system is rolled out at the customer's various international offices in several stages. The previous order, which was announced on January 25, 2019, concerned software. In this stage, hardware in the form of room panels has been ordered in an order worth SEK 2 million. In

Keliber updated DFS: Lithium hydroxide production significantly improves profitability

Keliber Oy’s Definitive Feasibility Study (“DFS”) for the lithium hydroxide production shows a significant improvement in profitability compared to previous assessments. The updated DFS shows a pre-tax NPV (8% discount rate) of EUR 510m, pre-tax IRR of 28% and a payback period of 3.7 years.Keliber Oy (“Keliber”) published the DFS for the Lithium Project (“the Project”) during summer 2018 based on the production of battery-grade lithium carbonate. However, Keliber estimated that lithium demand, especially from the cathode chemical, lithium-ion battery and electric vehicle manufacturers in

Updated Definitive Feasibility Study: Lithium hydroxide production significantly improves profitability of Keliber’s Lithium Project

The economic calculations of Keliber Oy’s Definitive Feasibility Study for the lithium hydroxide production show a significant improvement in profitability.Keliber Oy’s (“Keliber” or “the Company”) updated Definitive Feasibility Study for the lithium hydroxide production (“updated Definitive Feasibility Study” or “updated DFS”) confirms Lithium Project’s (“the Project”) strong financial and technical feasibility. All the key financial figures have improved significantly compared to the Definitive Feasibility Study based on lithium carbonate production (“DFS”) published in summer 2018.

Interim report January - December 2018

October - December · Net sales for the period increased with 19.4% to EUR 57.1 (47.8) million due to the acquisition of Sataservice from August 2018, partly offset by unfavorable currency effects and loss of a few contracts. Net sales declined organically with 1.9% compared to prior year · During the quarter three contracts were won, eight contracts were lost, and four contracts were renewed, which on balance affected the contract portfolio negatively. Portfolio run rate annualized net sales at the end of the quarter was EUR 205.5 (187.8) million · Operating loss improved to EUR -

Basware announces termination of discussions with Tradeshift Holdings Inc

Basware Corporation, stock exchange release, February 28, 2019 at 09:45 a.m. EETBasware Board of Directors today announces that is has terminated discussions with Tradeshift Holdings Inc (“Tradeshift”). In announcements in November and December 2018, Basware confirmed that it was in discussions with Tradeshift in relation to a possible cash tender offer by Tradeshift for all shares in Basware (the “Possible Offer”). Tradeshift has recently informed Basware that it will be unable to proceed given conditions in the capital markets. On this basis, the Board of Directors of Basware has

Year-end Report 2018

JANUARY–DECEMBER 2018 (COMPARED WITH JANUARY–DECEMBER 2017) ·Revenue increased by 42% to SEK 435.8 million (307.5) ·Net interest income increased by 46% to SEK 357.1 million (243.8) ·Adjusted Earnings before tax increased by 27% to SEK 152.2 million (119.5) ·Cost/income ratio decreased to 0.31 (0.32) ·The return on equity was 39% THE FOURTH QUARTER (COMPARED WITH THE FOURTH QUARTER OF 2017) ·Revenue increased by 6% to SEK 103.0 million (97.0) ·Net interest income increased by 10% to SEK 85.3 million (77.8) ·Earnings before tax

EAB Group Plc, Company Announcement, 28 February 2019, 9:30 a.m. (EET)

EAB Group Plc, Company Announcement, 28 February 2019, 9:30 a.m. (EET) Notice to the annual general meeting of EAB Group Plc EAB Group Plc's shareholders are invited to the Annual Meeting to be held on Friday 5 April 2019 at 09.30 EET at the Rake-Sali Ball Room, at Erottajankatu 4 C, Helsinki. The reception of participants enrolled to the meeting will begin at 08.30 EET. ITEMS ON THE AGENDA OF THE ANNUAL GENERAL MEETING 1. Opening of the meeting  2. Calling the meeting to order  3. Election of persons to scrutinise the minutes and to supervise the counting of votes

Interim Report January – December 2018

During the quarter we saw a more stable Swedish krona which reduced the negative currency effect on our earnings experienced previously. Also, we have seen positive effects from the previously announced program to increase profitability. Most of the activities to increase margins on products with low profitability have been implemented and we observed a positive trend in our profit levels compared to earlier quarters. The ongoing investment projects for the passenger car business went according to plan during the quarter and these investments continue also during the coming quarters. We

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 71,661,048 as a result of a partial registration of the preferential rights issue, resolved by the Board of Directors on 10 December 2018 and approved at the Extraordinary General Meeting on 17 January 2019.Today, the last trading day of the month, there are in total 163,358,124 shares and votes in NeuroVive Pharmaceutical AB.  This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to

NeuroVive Pharmaceutical AB Year End Report January - December 2018

Positioned for clinical progressImportant events January-December 2018 Quarter 1 · Positive experimental efficacy data for NVP025. · Decision on a rights issue (extraordinary general meeting). Quarter 2 · NeuroVive and Yungjin reports positive KL1333 phase I clinical study results. · KL1333 receives FDA Orphan Drug Designation for treatment of mitochondrial diseases. · Positive efficacy data in an experimental model, entailing a breakthrough for the NVP025 mitochondrial myopathy project. · NeuroVive initiates collaboration with leading US TBI research

Year-End Report 2018

Continue increase order intake and more customers Fourth quarter of 2018 · Net sales for the period amounted to SEK 6.8 (0.8) million and earnings to SEK -22.9 (-19.9) million, which corresponds to earnings per share of SEK -0.53 (-0.86). · Cash and cash equivalents on December 31 amounted to SEK 7.5 million. · A new order of SEK 4.5 million was received in December for Ångströmlaboratoriet in Uppsala. · After the acquisition the assets of I-Window International AB were acquired to broaden the product portfolio and strengthen the sales organization we see a positive

There are no items matching the current filter
There are no more items matching the current filter
Back to top